CIK 0001736730 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Camp4 Therapeutics Corp
Sign in to watch- Ticker
- CAMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-651-8867
- Business address
- 100 TALCOTT AVENUE, SUITE 201, WATERTOWN, MA, 02472
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Grant or award Director acquired 2,941,176 shares (grant or award)
- 4 Open-market buy 10% owner bought 2,941,176 shares at $1.53 ($4,499,999)
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 1,307,189 shares at $1.53 ($1,999,999)
- 4 Open-market buy Director bought 1,307,189 shares at $1.53 ($1,999,999)
- 4 Open-market buy Chief Medical Officer bought 6,060 shares at $1.65 ($9,999)
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy Chief Financial Officer bought 6,060 shares at $1.65 ($9,999)
- 4 Open-market buy Chief Executive Officer bought 6,060 shares at $1.65 ($9,999)
- 4 Open-market buy Director bought 15,151 shares at $1.65 ($24,999)
- 8-K Event Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 5 of 10 · 193 filings